Boston Scientific (BSX) Q4 2025 earnings review
Cardiovascular Boom Masks MedSurg Softness; Penumbra Acquisition Steals the Show
Boston Scientific capped a massive FY25 (Revenue +20%) with a Q4 beat, driven by the relentless momentum of its Cardiovascular unit (+16.1% organic). However, the growth curve is flattening—organic growth decelerated from 18% in Q1 to 12.7% in Q4. While the discontinuance of the ACURATE valve weighed on Europe, the headline news is the agreement to acquire Penumbra (NYSE: PEN), signaling aggressive expansion into thrombectomy. Guidance for 2026 suggests a normalization to ~10-11% organic growth, a step down from the hyper-growth of 2025.
🐂 Bull Case
The Cardiovascular segment remains a juggernaut, growing 16.1% organically in Q4. This was driven by U.S. sales surging 17%, fueled by the FARAPULSE PFA launch and WATCHMAN franchise. The segment is now nearly double the size of MedSurg.
The announcement to acquire Penumbra (thrombectomy) and Valencia Technologies, following the Axonics and Nalu deals, shows management is aggressively deploying capital to secure high-growth adjacencies rather than resting on current product cycles.
🐻 Bear Case
The 'law of large numbers' is kicking in. Organic growth slowed sequentially throughout 2025 (18.2% -> 17.4% -> 15.3% -> 12.7%). 2026 guidance calls for 8.5-10.0% organic growth in Q1, confirming the normalization trend.
While Cardiovascular soars, MedSurg is lagging significantly. MedSurg organic growth was just 6.5% in Q4, with Urology slowing to 3.2% organic growth—a sharp drop from the double-digit rates seen in prior years.
⚖️ Verdict: 🟢
Bullish. Despite the mathematical deceleration from peak 2025 levels, double-digit organic growth at $20B+ revenue scale is rare. The Penumbra acquisition creates a new long-term growth leg, masking softness in legacy MedSurg lines.
Key Themes
The Penumbra Acquisition
Boston Scientific announced the acquisition of Penumbra (NYSE: PEN), a major player in thrombectomy and neurovascular solutions. This is a transformative move that expands BSX's portfolio into high-growth stroke and peripheral embolization markets, reducing reliance on the cardiac rhythm and interventional cardiology cycles.
Urology Organic Growth Collapse
A significant red flag hidden in the print: Urology reported growth was strong at +13.8%, but this was driven entirely by acquisitions (likely Axonics). Organic growth plummeted to 3.2%, down from 5.4% in Q3 and 6.3% in Q2. This suggests the core legacy Urology business is facing stiff headwinds or competitive pressure.
ACURATE Valve Discontinuation Impact
Management discontinued worldwide sales of the ACURATE neo2 and Prime Aortic Valve Systems in Q2 2025. This created a specific headwind in EMEA, where sales grew only 4.8% operationally in Q4 compared to 17% in the U.S. The discontinuation removed ~$50M per quarter in revenue, dragging down international comps.
Electrophysiology (FARAPULSE) Supercycle
The Cardiovascular segment's 16.1% organic growth continues to be powered by the FARAPULSE PFA system. With U.S. sales growing 17% and the company securing new indications (e.g., persistent AFib labeling in Japan), the product cycle shows no signs of fatigue yet, though it faces tougher comps in 2026.
Margin Compression in Q4
Adjusted Operating Margin for Q4 came in at 27.3% (derived from $1,444M Adj Op Income / $5,286M Sales), which is a step down from the 28.9% seen in Q1 and 28.0% in Q3. This suggests some operating deleverage or increased investment spend (M&A integration costs) at year-end.
Other KPIs
Accelerating. BSX crossed the $20B milestone, delivering 19.9% reported growth and 15.8% organic growth for the year. This significantly outpaced the medtech peer group.
Stable. Beat the guidance range of $0.77-$0.79. However, the $0.80 print represents only slight sequential growth from Q3 ($0.75) and Q2 ($0.75), indicating earnings momentum is stabilizing after the H1 surge.
Decelerating. Down from 7.0% in Q2 and 7.9% in Q1 (calculated from segment data). The gap between Cardiovascular performance (16.1%) and MedSurg (6.5%) is widening.
Guidance
Decelerating. Down from the blistering 15.8% achieved in FY25. This reflects the law of large numbers and tougher comps, particularly for the PFA launch.
Decelerating. A clear step down from Q4's 12.7% and the prior Q1's 18.2%. This marks the first time in several quarters that organic growth is guided to single digits.
Accelerating. The midpoint ($3.46) implies ~13% YoY growth vs FY25's $3.06. While revenue slows, BSX expects to drive double-digit earnings growth, likely through margin management and share count discipline.
Key Questions
Urology Organic Weakness
Urology organic growth collapsed to 3.2% in Q4 from mid-single to high-single digits previously. Is this purely supply chain related, or is there a competitive share loss in the core stone/urology franchise?
Penumbra Integration Risk
With the Penumbra and Valencia acquisitions following closely on Axonics, is the organization stretched too thin on integration? How will this impact OpEx in 2026?
ACURATE Valve Strategy
With the discontinuation of ACURATE neo2 globally, does BSX have a viable strategy left in the TAVR space, or is the company effectively ceding the structural heart valve market to Edwards and Medtronic?
Tax Rate Headwinds
Previous calls mentioned a potential tax rate headwind in 2026. Does the FY26 EPS guidance fully bake in the impact of the global minimum tax (Pillar 2)?